Shanghai Bio-heart Biological Technology Co., Ltd. (HKG:2185)

HKG:2185 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Selling, General & Admin	19.74	52.88	94.37	195.42	81.56
Research & Development	41.3	111.74	157.83	214.23	245.74
Operating Expenses	61.04	164.62	252.2	409.65	327.3
Operating Income	-61.04	-164.62	-252.2	-409.65	-327.3
Interest Expense	-0.06	-0.58	-0.96	-0.69	-0.06
Interest & Investment Income	1.11	4	4.01	0.97	0.19
Earnings From Equity Investments	-0.99	-1.63	-1.43	-	-
Currency Exchange Gain (Loss)	0.92	1.73	18.68	-6.61	-16.35
Other Non Operating Income (Expenses)	0.39	0.91	1.04	6.15	3.22
EBT Excluding Unusual Items	-59.68	-160.2	-230.87	-409.83	-340.29
Gain (Loss) on Sale of Investments	-32.17	0.47	-	-	-
Gain (Loss) on Sale of Assets	-1.47	-30.51	-0	-	-
Other Unusual Items	-	1.42	-	-	-
Pretax Income	-93.32	-188.82	-230.87	-409.83	-340.29
Earnings From Continuing Operations	-93.32	-188.82	-230.87	-409.83	-340.29
Minority Interest in Earnings	5.38	12.93	26.63	48.38	14.77
Net Income	-87.94	-175.89	-204.24	-361.45	-325.52
Net Income to Common	-87.94	-175.89	-204.24	-361.45	-325.52
Shares Outstanding (Basic)	243	243	244	221	137
Shares Outstanding (Diluted)	243	243	244	221	137
Shares Change (YoY)	-	-0.14%	10.50%	61.54%	-
EPS (Basic)	-0.36	-0.72	-0.84	-1.64	-2.38
EPS (Diluted)	-0.36	-0.72	-0.84	-1.64	-2.38
Free Cash Flow	-166.69	-66.74	-170.65	-122.75	-54.24
Free Cash Flow Per Share	-0.69	-0.27	-0.70	-0.56	-0.40
EBITDA	-54.25	-148.21	-237.34	-400.88	-319.76
D&A For EBITDA	6.79	16.41	14.87	8.77	7.54
EBIT	-61.04	-164.62	-252.2	-409.65	-327.3

Source: S&P Global Market Intelligence. Standard template. Financial Sources.